Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Liwanli Innovation CoTPE:3054 +6.03%62 EV-to-EBIT is 8.91 as of Aug. 27, 2026, which is 50% below its 10-year median of 17.75. GuruFocus rates TPE:3054 with a GF Score™ of 62/100 and a GF Value™ of NT$119.46 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 691 Drug Manufacturers companies, Liwanli Innovation Co ranks better than 75.54% on this metric.
Liwanli Innovation Co (TPE:3054) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Liwanli Innovation Co's Enterprise Value for the quarter that ended in Jun. 2026 was NT$4,355.2 Mil.
Liwanli Innovation Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$413.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Liwanli Innovation Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Liwanli Innovation Co EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Liwanli Innovation Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Liwanli Innovation Co's EV-to-EBIT falls into.
Liwanli Innovation Co's current Enterprise Value is NT$3,685.8 Mil.
Liwanli Innovation Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$413.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Liwanli Innovation Co (TPE:3054) has a EV-to-EBIT of 8.91 as of Aug. 27, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Liwanli Innovation Co and its competitors. This is 50% below median its historical median of 17.75. According to the industry distribution chart, Liwanli Innovation Co ranks #169 out of 691 companies in the Drug Manufacturers industry, placing it in the top 24.5%.
Is Liwanli Innovation Co's EV-to-EBIT too high?
Liwanli Innovation Co's current EV-to-EBIT of 8.91 is 50% below median its 10-year median of 17.75. The Drug Manufacturers industry median EV-to-EBIT is 15.77. Liwanli Innovation Co's value of 8.91 is 43.5% below this industry median. Based on the distribution chart, Liwanli Innovation Co ranks #169 out of 691 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Liwanli Innovation Co has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Liwanli Innovation Co's EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Liwanli Innovation Co ranks #169 out of 691 companies for EV-to-EBIT. This places Liwanli Innovation Co in the top 25% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 15.77. Liwanli Innovation Co's value of 8.91 is 43.5% below this benchmark. While the company's 10-year median is 17.75 vs. the industry median of 15.77, Liwanli Innovation Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.77, based on 691 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Liwanli Innovation Co's current EV-to-EBIT of 8.91 is 43.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Liwanli Innovation Co and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Liwanli Innovation Co's current EV-to-EBIT is 8.91, which is 50% below median its own 10-year median of 17.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Liwanli Innovation Co stock overvalued right now?
Based on GuruFocus' analysis, Liwanli Innovation Co (TPE:3054) is currently considered Possible Value Trap. The stock's GF Value™ is NT$119.46, compared to a current price of NT$54.50 — trading 54.4% below its estimated fair value. The current EV-to-EBIT is 8.91, which is 50% below median its 10-year median of 17.75 and 43.5% below the Drug Manufacturers industry median of 15.77. Liwanli Innovation Co's overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Liwanli Innovation Co (TPE:3054), the current EV-to-EBIT is 8.91 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Liwanli Innovation Co (TPE:3054) Overvalued in 2026?
Based on GuruFocus' analysis, Liwanli Innovation Co stock appears to be undervalued.
The current stock price of NT$54.50 is trading 54.4% below its estimated GF Value™ of NT$119.46.
GuruFocus considers Liwanli Innovation Co to be Possible Value Trap.
Key valuation signals for TPE:3054:
EV-to-EBIT: 8.91 (50% below median its 10-year median of 17.75)
GF Value™: NT$119.46 vs. price of NT$54.50 (54.4% below fair value)
Industry Position: 43.5% below the Drug Manufacturers median (#169 of 691)
No single metric tells the full story. See the TPE:3054 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Liwanli Innovation Co Ltd is engaged in the manufacture, wholesale, and retail of electronic materials and the sales of biotech products like drug nutrient products. The reportable segments of the company are distinguished by products; the electronic department is mainly engaged in the sale and after-sales service of computer peripherals, memory and other related products; and the biotechnology department is mainly engaged in the sales of biotechnology products. Maximum revenue is generated from its Electronics department. Geographically, it generates a majority of its revenue from Taiwan, followed by other regions.
62GF Score
Get the complete analysis for TPE:3054
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:3054 has been successfully added to your 
